This presentation encompassed many important issues - it's worth the watch - I will try to answer questions you may have.
We are awaiting the data from several clinical trials which may potentially change treatments of Cholangiocarcinoma patients.
Although the majority of physicians recommend adjuvant (post resection) chemotherapy, the outcome of the (3) below mentioned clinical research studies will prove/disprove the validity of this approach.
Do extrahepatic (hilar and distal) resected CCA patients benefit from adjuvant therapy with Capecitabine (Xeloda?
Do extrahepatic (hilar and distal) resected CCA patients benefit from adjuvant GEMOX treatment?
Do CCA (intrahepatic, hilar, distal) resected patients benefit from adjuvant GEM/CIS treatment?
The below study is comparing progression free survival of extrahepatic (hilar, distal) CCA with advanced or metastatic disease, who have been treated with Gem/Cis as first line of treatment but now have progressed.
Is XELOX as effective as GEMOX?
The ABC-6 study
CCA patients (intrahepatic, distal, hilar) non metastatic, but locally advanced, who are fully active, able to carry on all pre-disease performance without restriction or may be restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. One arm (group) of participants will receive monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
The other control group will receive FOLFOX.
Intrahepatic, non-resectable, localized progressed (non-metastatic) CCA patients are divided in 2 groups:
Group A: will receive Gem/Cis
Group B: will receive Gem/Cis plus radiation. With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed By Surgery